[
  {
    "ts": null,
    "headline": "Does EMA Support for High Dose Nusinersen Redefine the Bull Case for Biogen (BIIB)?",
    "summary": "In November 2025, Biogen received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use recommending approval of a high dose nusinersen regimen for 5q spinal muscular atrophy, with a final European Commission decision expected by January 2026. This regulatory progress not only has the potential to expand treatment options for SMA patients in Europe but also strengthens Biogen’s position within the neurological disease treatment market. We'll...",
    "url": "https://finnhub.io/api/news?id=95fcb331f6f8580c156a71292a47484be073792f15f27e26e09d741a4b4519d5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763831989,
      "headline": "Does EMA Support for High Dose Nusinersen Redefine the Bull Case for Biogen (BIIB)?",
      "id": 137579218,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "In November 2025, Biogen received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use recommending approval of a high dose nusinersen regimen for 5q spinal muscular atrophy, with a final European Commission decision expected by January 2026. This regulatory progress not only has the potential to expand treatment options for SMA patients in Europe but also strengthens Biogen’s position within the neurological disease treatment market. We'll...",
      "url": "https://finnhub.io/api/news?id=95fcb331f6f8580c156a71292a47484be073792f15f27e26e09d741a4b4519d5"
    }
  }
]